Five days ago, the embattled Israeli government announced “a road map to legalize cannabis within one year” creating a regulated market for adult-use marijuana.
October 14, 2020 Isracann announced that “the government of Israel has officially enacted the legislation for the export of medical cannabis, clearing the way for sales abroad that the government expects could generate more than 1 billion shekels ($273 million) in annual revenue.”
Isracann and Tinley update shareholders
The beginning of recreational weed in Israel is likely to boost IPOT’s bottom line.
The Israeli Ministry of Economy signed a Free Export Order for medical cannabis last month. The order allows for the implementation of an earlier decision
Isracann Biosciences (IPOT.C) is accelerating efforts to service an anticipated increase in demand for both domestic and EU markets. Isracanna is Israel’s only pure pot
“We have achieved a partnership agreement with a farm operation that is constructed,” stated Isracann CEO, Darryl Jones, “it has already closed a major offtake agreement for the next three years. This accelerates our timeline to production and revenue.”
There’s a lot going on underneath the surface with Isracann Biosciences (IPOT.C). A year in review won’t be much, mostly because this company hasn’t been
On December 17, 2019 Isracann (IPOT.C) announced that it has entered into an Memorandum of Understanding (MOU) for a joint venture (JV) with an additional
Isracann BioSciences (IPOT) is the first pure pot play growing in the Promised Land. You may not think this middle east nation state is a
Isracann Biosciences (IPOT.C) got the regulatory nod from the Israeli Land Authority for their land use and facility design, but before they can get started
Isracann Biosciences (IPOT.C), an Israel-based cannabis play, has engaged the services of LinC by Growing Smart to draw a project roadmap for their proposed 230,000
Being “original” in business is a double-edged sword. Yes – it’s good to stand out in the crowd. But – when you’re all alone –
As a general rule, I’m against any company with ‘cann’ or ‘canna’ in its title. You could make a drinking game out of reading the
A few days ago, I published a story about our friends from HIKU/Tokyo Smoke/Doja/Saxx who, having exited from their last company with a $400m+ acquisition
